eligibility_summary
Eligibility: ≥2 prior therapies with no standard options, adequate organ function, measurable disease, ECOG 0–1, life expectancy ≥12 wks, contraception and negative pregnancy test, tumor tissue or biopsy, prior CAR‑T ≥90 d. Exclusions: Burkitt/lymphoblastic or CNS lymphoma, allo SCT (FL/MCL >100 d, no GvHD), solid organ tx, auto SCT ≤100 d, major CV/QTcF>480, autoimmune disease, recent anticancer therapy or surgery, active infection, HBV PCR+, HIV/HCV active, live vaccine, other cancer <2 yrs.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
NCT06392477 is a Phase 1, multicenter, dose-escalation/expansion study in relapsed/refractory B‑cell non‑Hodgkin lymphoma testing DR‑0201. Intervention: DR‑0201, a bispecific antibody (immunotherapy biologic), given for up to 12 months across multiple dose levels (0.3–500 mg). Mechanism: DR‑0201 is designed to bind two targets, the specific antigens and exact effector mechanism are not disclosed in the registry. As a class, bispecific antibodies typically redirect immune effector activity to tumors. Target cells/pathways: malignant B cells in B‑NHL, engagement of immune effector pathways to mediate B‑cell killing. Precise B‑cell antigens and whether T cells, NK cells, or Fc functions are engaged are not specified.